Theyre now teaming up with other companies to develop this treatment and aim to start human trials in 2026 or 2027
Options include: brand-name Wegovy or Zepbound (covered by some insurance plans), the new Medicare GLP-1 Bridge ($50/month for eligible Medicare beneficiaries starting July 2026), Foundayo (orforglipron, $149/month oral pill), manufacturer patient assistance programs, or transitioning to a 503A compounding pharmacy if a documented clinical need exists (such as an allergy to an inactive ingredient)
After investigating over 1,000 different plant compounds in vitro, the researchers concluded that a native New Zealand hops extract produced the strongest TAS2R stimulation and consequential enhanced release of anorexigenic (GLP-1, CCK and PYY) hormonal response, indicating the strongest appetite suppressant effect
This emerging literature reflects clinical awareness that weight loss quality matters alongside quantity
The harsh high-altitude environment, characterized by low ambient oxygen and low temperatures, can exacerbate preexisting lung diseases such as chronic bronchitis, emphysema, asthma, and obstructive lung disease, leading to hypoxemia and secondary polycythemia
Possible bowel obstruction